



May 15, 2020

Dept. of Corporate Services
BSE Ltd.
P J Towers,
Dalal Street,
Mumbai – 400 001.

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai 400051.

BSE Scrip Code : 524735

NSE Symbol : HIKAL

Dear Sir,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are pleased to inform you that Hikal Limited, a leading manufacturer and supplier of API's and intermediates globally today announced the successful development of Favipiravir Active Pharmaceutical ingredient (API) and its intermediates. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19.

The company is in discussion with potential partners to supply the API and its intermediates.

Hikal has developed this API in a record amount of time to make the product available for treatment of COVID-19. This demonstrates Hikal's commitment to support in the fight against COVID-19 virus and to provide high quality medicines to its customers globally.

Any further developments will be informed promptly.

Thanking You,

Yours faithfully,

for **HIKAL LTD.,**

Sd/-
Sham Wahalekar
President - Finance &
Company Secretary

Hikal Ltd.

Admin. Office: Great Eastern Chambers, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel: +91-22-3097 3100. Fax: +91-22-3097 3281

Regd. Office: 717, Maker Chamber - 5, Nariman Point, Mumbai - 400 021, India. Tel.: +91-22-6277 0477, +91-22-3926 7100. Fax: +91-22-2283 3913

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028